Accuracy of N-terminal pro-brain natriuretic peptide in the identification of left ventricular dysfunction in high-risk asymptomatic patients

Journal of Cardiovascular Medicine

Volumn 10, Issue 3, 2009, Pages 238-244

  Romano, Silvio ^a   Necozione, Stefano ^a   Guarracini, Leonello ^b   Fratini, Simona ^a   Cisternino, Pasquale ^b   Di Orio, Ferdinando ^a   Penco, Maria ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Division of Cardiac Rehabilitation   (Italy)

Author keywords

Brain natriuretic peptides; Echocardiography; Heart failure; Left ventricular dysfunction

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; ANTIHYPERTENSIVE THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; FEMALE; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SMOKING; SYSTOLIC DYSFUNCTION; BLOOD; DOPPLER ECHOCARDIOGRAPHY; HEART STROKE VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PREDICTION AND FORECASTING; REPRODUCIBILITY; RISK; ROC CURVE; UPREGULATION;

BIOLOGICAL MARKERS; ECHOCARDIOGRAPHY, DOPPLER, COLOR; ECHOCARDIOGRAPHY, DOPPLER, PULSED; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; ODDS RATIO; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; ROC CURVE; SENSITIVITY AND SPECIFICITY; STROKE VOLUME; UP-REGULATION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 63049100612     PISSN: 15582027     EISSN: None     Source Type: Journal    
DOI: 10.2459/JCM.0b013e3283212ee0     Document Type: Article

References (37)

1. Bonneux L, Barendregt JJ, Meeter K, Bousel GJ, van der Maas PJ. Estimating clinical morbidity due to ischemic heart disease and congestive heart failure: the future rise of heart failure. Am J Public Health 1994; 84:20-28. (Pubitemid 24023506)
2. McMurray J, McDonagh TA, Morrison CE, Dargie HJ. Trends in hospitalisation for heart failure in Scotland 1980-1990. Eur Heart J 1993; 14:1158-1162.
3. Ghjali JK, Cooper R, Ford E. Trends in hospitalisation rates for heart failure in the United States, 1973-1986. Evidence for increasing population prevalence. Arch Intern Med 1990; 150:769-773.
4. Wang TJ, Evans JC, Benjamin EJ, Levy D, LeRoy EC, Vasan RS. Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 2003; 108:977-982. (Pubitemid 37048228)
5. Wang TJ, Levy D, Benjamin EJ, Vasan RS. The epidemiology of 'asymptomatic' left ventricular systolic dysfunction: implications for screening. Ann Intern Med 2003; 138:907-916.
6. McDonagh TA, Morrison CE, Lawrence A, Ford I, Tunstall-Pedoe H, McMurray JJ, Dargie HJ. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350:829-833. (Pubitemid 27404343)
7. Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary - a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2001; 38:2101-2113.
8. The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005). Eur Heart J 2005; 26:1115-1140.
9. McDonagh TA, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351:9-13. (Pubitemid 28020159)
10. Yamamoto K, Burnett JC Jr, Bermudez EA, Jougasaki M, Bailey KR, Redfield MM. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail 2000; 6:194-200. (Pubitemid 30683545)
11. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Heart J 2001; 141:367-374. (Pubitemid 32200264)
12. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet 2003; 362:316-322. (Pubitemid 36936846)
13. Vasan RS, Benyamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, et al. Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction. The Framingham Heart Study. JAMA 2002; 288:1252-1259.
14. Senior R, Galasko G, McMurray JV, Mayet J. Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides. Heart 2003; 89 (Suppl 3):iii24-iii28. (Pubitemid 37311142)
15. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction. A community-based study. Circulation 2004; 109:3176-3181.
16. Takase H, Toriyama T, Sugiura T, Takahashi A, Sugiyama M, Ohashi M, et al. Brain natriuretic peptide detects cardiac abnormalities in mass screening. Eur J Clin Invest 2007; 37:257-262. (Pubitemid 46439413)
17. Latour-Pérez J, Coves-Orts FJ, Abad-Terrado C, Abraira V, Zamor J. Accuracy of B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction and heart failure: a systematic review. Eur J Heart Fail 2006; 8:390-399. (Pubitemid 43842121)
18. Goetze JP, Mogelvang R, Maage L, Scharling H, Schnohr P, Sogaard P, et al. Plasma pro-B-type natriuretic peptide in the general population screening for left ventricular hypertrophy and systolic dysfunction. Eur Heart J 2006; 27:3004-3010. (Pubitemid 44950445)
19. Sackett DL, Haynes RB. The architecture of diagnostic research. Br Med J 2002; 324:539-541.
20. Mueller T, Gegenhuber A, Poelz W, Haltmaver M. Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 2004; 341:41-48. (Pubitemid 38210312)
21. Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. Use of NTproBNP in routine testing and comparison to BNP. Eur J Heart Fail 2004; 6:289-293. (Pubitemid 38253047)
22. Steiner J, Guglin M. BNP or NTproBNP: a clinician's perspective. Int J Cardiol 2008; 129:5-14.
23. Devereux RB, Roman MJ, Paranicas M, Lee ET, Welty TK, Fabsitz RR, et al. A population-based assessment of left ventricular systolic dysfunction in middle-aged and older adults: the Strong Heart Study. Am Heart J 2001; 141:439-446. (Pubitemid 32200274)
24. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, Rodeheffer RJ. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 2003; 289:194-202.
25. Goetze JP, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrup J, Nielsen LB. Increased cardiac BNP expression associated with myocardial ischemia. FASEB J 2003; 17:1105-1107.
26. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. Btype natriuretic peptide and ischemia in patients with stable coronary disease. Data from Heart and Soul Study. Circulation 2003; 108: 2987-2992.
27. Nielsen OW, McDonagh TA, Robb SD, Dargie HJ. Retrospective analysis of the cost-effectiveness of using plasma brain natriuretic peptide in screening for left ventricular systolic dysfunction in the general population. J Am Coll Cardiol 2003; 41:113-120. (Pubitemid 36044412)
28. Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG. Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 2004; 43:1019-1026.
29. Omland T, de Lemos JA, Morrow DA, Antman EM, Cannon CP, Hall C, et al. Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 2002; 89:463-465. (Pubitemid 34142525)
30. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005; 352:666-675. (Pubitemid 40239214)
31. De Sutter J, De Bacquer D, Cuypers S, Delanghe J, De Buyzere M, Kornitzer M, et al. Plasma N-terminal pro-brain natriuretic peptide concentration predicts coronary event in men at work: a report from the BELTRESS study. Eur Heart J 2005; 26:2644-2649. (Pubitemid 41746686)
32. Kook H, Itoh H, Choi BS, Sawada N, Doi K, Hwang TJ, et al. Physiological concentration of atrial natriuretic peptide induces endothelial regeneration in vitro. Am J Physiol Heart Circ Physiol 2003; 284:H1388-H1397. (Pubitemid 36348603)
33. Brunner F, Wolkart G. Relaxant effect of C-type natriuretic peptide involves endothelium and nitric oxide-cGMP system in rat coronary microvasculature. Cardiovasc Res 2001; 51:577-584. (Pubitemid 32718606)
34. Kohno M, Yokokawa K, Yasunari K, Kano H, Minami M, Ueda M, et al. Effect of natriuretic peptide family on the oxidized LDL-induced migration of human coronary artery smooth muscle cells. Circ Res 1997; 81:585-590. (Pubitemid 27432746)
35. Herring N, Zaman JA, Paterson DJ. Natriuretic peptides like NO facilitate cardiac vagal neurotransmission and bradycardia via cGMP pathway. Am J Physiol Heart Circ Physiol 2001; 281:H2318-H2327. (Pubitemid 33776603)
36. Goetze JP. Coronary artery disease, heart failure, and cardiac natriuretic peptides in the middle. Eur Heart J 2005; 26:2603-2604. (Pubitemid 41746674)
37. Costello-BoerrigterLC,Boerrigter G,RedfieldMM,Rodeheffer RJ, Urban LH, Mahoney DW,et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community. Determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 2006; 47:345-353.